Inocras Raises $31 Million to Accelerate U.S. Expansion of Whole-Genome Sequencing Platform for Precision Oncology
Inocras Inc., a bioinformatics-driven precision medicine company specializing in whole-genome sequencing (WGS) and advanced genomic analytics, has announced the successful completion of an oversubscribed $31 million Series B-3 financing round. The new investment marks another significant milestone in the company’s growth journey, bringing its total capital raised to approximately $100 million.
The latest funding will be used to accelerate the company’s expansion into the United States, where it plans to broaden access to its comprehensive whole-genome sequencing platform for cancer diagnosis and treatment. Building on years of clinical deployment throughout Asia, Inocras aims to establish its technology as a key component of precision oncology by providing clinicians with highly curated, clinically actionable genomic insights that support personalized cancer care.
Strengthening the Future of Whole-Genome Sequencing
As precision medicine continues to evolve, whole-genome sequencing is increasingly being recognized as one of the most comprehensive approaches to understanding cancer biology. Unlike targeted gene panels or exome sequencing, whole-genome sequencing evaluates nearly every region of a patient’s genome, enabling the detection of a broad spectrum of genetic alterations that may influence diagnosis, prognosis, treatment selection, and disease monitoring.
Inocras has positioned itself at the forefront of this transformation by combining large-scale genomic sequencing with proprietary bioinformatics software capable of converting highly complex genomic data into reports that clinicians can readily interpret and apply in patient care.
The company believes that comprehensive genomic analysis will become an increasingly important tool as oncologists seek more personalized treatment strategies for patients with both common and rare cancers.
Oversubscribed Financing Reflects Investor Confidence
The Series B-3 financing attracted strong interest from both new and existing investors, reflecting growing confidence in Inocras’s technology platform, commercial strategy, and long-term vision for precision oncology.
Strategic investors participating in the financing include:
- NDS Corporation
- Aimed Bio Inc.
The round also welcomed several new financial investors, including:
- IMM Investment
- Korea Investment & Securities
- LoftyRock Investment
- DT& Investment
- Woori Investment & Securities
- Shinhan Securities
In addition, several existing investors increased their commitments, including:
- DSC Investment
- Dunamu & Partners
- InterVest
The participation of both institutional investors and strategic healthcare companies demonstrates confidence in the growing role that whole-genome sequencing may play in future cancer management.
Building Upon Proven Clinical Success in Asia
Unlike many emerging genomics companies that are still validating their technologies, Inocras enters the U.S. market with extensive real-world clinical experience accumulated across Asia.
The company’s whole-genome sequencing solutions are currently being utilized by more than 100 cancer institutions, supporting physicians across thousands of patient cases.
Its commercial footprint includes a particularly strong presence in:
- South Korea
- Hong Kong
- Other healthcare institutions throughout Asia
In South Korea alone, Inocras supports approximately 30 hospitals, where its genomic analysis platform assists clinicians in making informed treatment decisions for cancer patients.
This broad clinical adoption provides valuable evidence that the company’s sequencing and interpretation platform can function effectively in routine clinical practice rather than remaining limited to research settings.
Transforming Complex Genomic Data into Clinical Insights
One of the major challenges in implementing whole-genome sequencing is not generating the data itself, but interpreting the enormous amount of information produced by each patient’s genome.
Each sequencing run identifies millions of genetic variants, many of which may have little or no clinical significance.
Inocras has focused heavily on solving this challenge through proprietary bioinformatics algorithms and automated interpretation technologies.
Rather than overwhelming physicians with raw sequencing data, the company’s software analyzes genetic alterations across the entire cancer genome and organizes the findings into clinically relevant reports.
These reports help physicians better understand:
- Driver mutations
- Structural genomic alterations
- Copy number variations
- Complex biomarkers
- Genomic signatures
- Potential therapeutic targets
- Biomarkers associated with treatment response
- Disease progression indicators
This approach enables healthcare providers to incorporate sophisticated genomic information into clinical decision-making more efficiently.
CancerVision™ Supports Comprehensive Tumor Profiling
A central component of Inocras’s precision oncology portfolio is CancerVision™, its comprehensive tumor profiling solution.
CancerVision leverages whole-genome sequencing to characterize tumors in greater detail than conventional testing methods.
The platform evaluates genomic alterations throughout the entire cancer genome rather than limiting analysis to predefined gene panels.
This comprehensive strategy enables clinicians to uncover potentially actionable genomic findings that may otherwise remain undetected using narrower testing approaches.
CancerVision supports precision oncology by providing a more complete molecular profile that may help guide targeted therapy selection, clinical trial enrollment, and personalized treatment planning.
MRDVision™ Enables Molecular Residual Disease Monitoring
Alongside tumor profiling, Inocras has developed MRDVision™, a solution focused on detecting molecular residual disease (MRD).
MRD testing is becoming an increasingly valuable component of cancer management because it can identify minute amounts of residual cancer DNA that remain after treatment.
Detecting these residual cancer cells earlier than conventional imaging methods may provide physicians with important information regarding:
- Treatment effectiveness
- Risk of recurrence
- Disease monitoring
- Therapeutic adjustments
MRDVision applies whole-genome sequencing and proprietary analytics to monitor patients following therapy, offering clinicians another tool to personalize long-term cancer management.
Expanding Into the United States
The new financing will primarily support Inocras’s commercial expansion throughout the United States.
The company plans to invest in several strategic initiatives, including:
- Expanding commercial operations
- Building additional clinical partnerships
- Growing laboratory capabilities
- Increasing operational infrastructure
- Supporting hospital adoption
- Strengthening customer support
- Expanding scientific collaborations
- Generating additional clinical evidence
The U.S. represents one of the world’s largest precision medicine markets, with increasing demand for advanced genomic testing as targeted therapies and personalized treatment strategies continue to expand.
By leveraging its existing clinical experience from Asia, Inocras hopes to accelerate adoption among U.S. healthcare providers.
Advancing Precision Oncology Through Bioinformatics
While sequencing technologies have become increasingly accessible, extracting clinically meaningful information remains a significant challenge.
Inocras differentiates itself through its emphasis on bioinformatics, automation, and curated clinical interpretation.
Its proprietary software integrates multiple layers of genomic information into reports designed to support oncologists, pathologists, and molecular tumor boards.
The company’s approach reduces the burden of manual interpretation while increasing consistency across clinical cases.
As precision oncology becomes more data-intensive, sophisticated computational platforms like those developed by Inocras are expected to play an increasingly important role in translating genomic information into patient care.
Scientific Validation Supports Clinical Adoption
The company’s expansion efforts are supported by continued scientific validation of its whole-genome sequencing platform.
Through a collaboration with researchers at the Broad Institute, Inocras recently analyzed whole-genome sequencing data from The Cancer Genome Atlas (TCGA) involving thousands of cancer cases.
The research demonstrated the potential value of standardized whole-genome analysis across diverse cancer types while highlighting the importance of comprehensive genomic characterization for precision oncology.
Such collaborations strengthen the evidence supporting broader implementation of whole-genome sequencing in clinical oncology and reinforce confidence in the company’s analytical capabilities.
Leadership Highlights Future Growth Strategy
Commenting on the financing, Jehee Suh, Chief Executive Officer of Inocras, emphasized that the company’s strong clinical adoption throughout Asia provides a solid foundation for expansion into the United States.
According to Suh, thousands of patients have already benefited from Inocras’s technology across numerous cancer institutions, demonstrating the platform’s ability to deliver clinically useful genomic insights in real-world healthcare settings.
He noted that the company’s next major objective is to bring this experience to the U.S. market and help establish whole-genome sequencing as a standard component of routine cancer care. The newly secured funding will enable Inocras to expand its clinical presence, support adoption within hospitals, strengthen commercial operations, and continue building the scientific evidence needed to drive broader implementation of comprehensive genomic testing.
With approximately $100 million in total funding, a growing international customer base, proven clinical deployment across Asia, and continued investment in bioinformatics innovation, Inocras is well positioned to expand its role in the rapidly evolving precision oncology landscape.
As healthcare systems increasingly recognize the value of comprehensive genomic profiling, the company aims to bridge the gap between complex whole-genome sequencing data and practical clinical decision-making. Through continued technological development, strategic partnerships, and expansion into the United States, Inocras seeks to make whole-genome sequencing more accessible and help clinicians deliver increasingly personalized treatment strategies for cancer patients worldwide.
About Inocras
Inocras is a bioinformatics-led company redefining precision health through whole genome data and proprietary analytics. Our oncology and rare disease platforms integrate comprehensive whole genome data with advanced automation to deliver curated and actionable insights at scale that accelerate discovery and diagnostics to improve patient care, bringing a real-world impact.
Inocras operates a CLIA/CAP-certified laboratory and partners with leading hospitals, pharmaceutical companies, and research institutions worldwide. For more information, please visit inocras.com and follow the Inocras LinkedIn page.